What does CUSIP 92532F100 represent in this 13F holders report?

CUSIP 92532F100 is the security identifier for VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock used to aggregate holder disclosures.

How many institutions held VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock in Q2 2016?

473 institutional investors reported VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock for Q2 2016. Use the holders table for investor-level position and value details.

VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

CUSIP: 92532F100

Q2 2016 13F Holders as of 30 Jun 2016

Type / Class: Equity / Common Stock
Shares outstanding: 254,691,824
Total 13F shares: 239,982,115
Share change: +2,697,680
Total reported value: $20,645,253,416
Put/Call ratio: 81%
Price per share: $86.02
Number of holders: 473
Value change: +$255,018,558
Number of buys: 237
Number of sells: 218

Quarterly Holders Quick Answers

What is CUSIP 92532F100?
CUSIP 92532F100 identifies VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2016
Previous quarter: Q1 2016

Recent filing periods for CUSIP 92532F100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	9.8%	25,008,493	$1,987,925,000	—	31 Mar 2016	13F
Capital World Investors	13F	Company	8.5%	21,598,162	$1,716,838,000	—	31 Mar 2016	13F
FMR LLC	13F	Company	5.9%	15,134,753	$1,203,062,000	—	31 Mar 2016	13F
VANGUARD GROUP INC	13F	Company	5.9%	14,935,838	$1,187,250,000	—	31 Mar 2016	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	5.8%	14,727,173	$1,170,662,000	—	31 Mar 2016	13F
JPMORGAN CHASE & CO	13F	Company	4.6%	11,688,327	$929,105,000	—	31 Mar 2016	13F
STATE STREET CORP	13F	Company	3.8%	9,790,008	$778,214,000	—	31 Mar 2016	13F
AMERIPRISE FINANCIAL INC	13F	Company	3.7%	9,403,147	$747,465,000	—	31 Mar 2016	13F
Clearbridge Investments, LLC	13F	Company	3%	7,623,324	$605,978,000	—	31 Mar 2016	13F
BlackRock Institutional Trust Company, N.A.	13F	Company	2.5%	6,338,154	$503,820,000	—	31 Mar 2016	13F
BlackRock Fund Advisors	13F	Company	2.3%	5,852,428	$465,210,000	—	31 Mar 2016	13F
WADDELL & REED FINANCIAL INC	13F	Company	1.8%	4,561,643	$362,605,000	—	31 Mar 2016	13F
GOLDMAN SACHS GROUP INC	13F	Company	1.7%	4,409,972	$350,549,000	—	31 Mar 2016	13F
Invesco Ltd.	13F	Company	1.3%	3,325,110	$264,314,000	—	31 Mar 2016	13F
Bank of New York Mellon Corp	13F	Company	1.2%	3,166,038	$251,669,000	—	31 Mar 2016	13F
NORTHERN TRUST CORP	13F	Company	1.1%	2,913,003	$240,061,000	—	31 Mar 2016	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	1.2%	2,953,715	$234,790,000	—	31 Mar 2016	13F
BlackRock Group LTD	13F	Company	0.84%	2,132,681	$169,525,000	—	31 Mar 2016	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.78%	1,986,187	$157,561,000	—	31 Mar 2016	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.78%	1,979,217	$157,328,000	—	31 Mar 2016	13F
FRED ALGER MANAGEMENT, LLC	13F	Company	0.77%	1,968,489	$156,475,000	—	31 Mar 2016	13F
ORBIMED ADVISORS LLC	13F	Company	0.73%	1,869,400	$148,599,000	—	31 Mar 2016	13F
BLACKROCK ADVISORS LLC	13F	Company	0.73%	1,855,988	$147,532,000	—	31 Mar 2016	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.69%	1,756,022	$139,586,000	—	31 Mar 2016	13F
BlackRock Investment Management, LLC	13F	Company	0.68%	1,723,031	$136,964,000	—	31 Mar 2016	13F
NORGES BANK	13F	Company	0.68%	1,720,494	$136,763,000	—	31 Mar 2016	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.58%	1,467,300	$116,635,000	—	31 Mar 2016	13F
BB BIOTECH AG	13F	Company	0.54%	1,365,445	$108,539,000	—	31 Mar 2016	13F
OppenheimerFunds, Inc.	13F	Company	0.49%	1,235,305	$98,193,000	—	31 Mar 2016	13F
TIAA CREF INVESTMENT MANAGEMENT LLC	13F	Company	0.48%	1,220,014	$96,979,000	—	31 Mar 2016	13F
DEUTSCHE BANK AG\	13F	Company	0.47%	1,194,474	$94,943,000	—	31 Mar 2016	13F
D. E. Shaw & Co., Inc.	13F	Company	0.45%	1,146,335	$91,122,000	—	31 Mar 2016	13F
GENERAL ELECTRIC CO	13F	Company	0.44%	1,110,952	$88,310,000	—	31 Mar 2016	13F
JENNISON ASSOCIATES LLC	13F	Company	0.41%	1,054,142	$83,794,000	—	31 Mar 2016	13F
Tekla Capital Management LLC	13F	Company	0.41%	1,033,503	$82,153,000	—	31 Mar 2016	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.4%	1,023,376	$81,348,000	—	31 Mar 2016	13F
THRIVENT FINANCIAL FOR LUTHERANS	13F	Company	0.4%	1,007,732	$80,104,000	—	31 Mar 2016	13F
Senator Investment Group LP	13F	Company	0.39%	1,000,000	$79,490,000	—	31 Mar 2016	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.39%	995,248	$79,112,000	—	31 Mar 2016	13F
FRANKLIN RESOURCES INC	13F	Company	0.39%	990,015	$78,696,000	—	31 Mar 2016	13F
LAZARD ASSET MANAGEMENT LLC	13F	Company	0.39%	982,343	$78,085,000	—	31 Mar 2016	13F
Legal & General Group Plc	13F	Company	0.38%	976,361	$77,611,000	—	31 Mar 2016	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.37%	945,666	$75,171,000	—	31 Mar 2016	13F
JANUS HENDERSON INVESTORS US LLC	13F	Company	0.35%	898,666	$71,436,000	—	31 Mar 2016	13F
SECTORAL ASSET MANAGEMENT INC	13F	Company	0.35%	896,479	$71,261,000	—	31 Mar 2016	13F
AMUNDI ASSET MANAGEMENT US, INC.	13F	Company	0.34%	876,770	$69,695,000	—	31 Mar 2016	13F
Point72 Asset Management, L.P.	13F	Company	0.33%	838,700	$66,668,000	—	31 Mar 2016	13F
abrdn Investment Management Ltd	13F	Company	0.31%	777,628	$61,848,000	—	31 Mar 2016	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.27%	697,700	$55,460,000	—	31 Mar 2016	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.27%	679,656	$54,026,000	—	31 Mar 2016	13F

Institutional Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q2 2016

As of 30 Jun 2016, VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) was held by 473 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 239,982,115 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, FMR LLC, Capital World Investors, VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, JPMORGAN CHASE & CO, STATE STREET CORP, AMERIPRISE FINANCIAL INC, Clearbridge Investments, LLC, and BlackRock Institutional Trust Company, N.A.. This page lists 474 institutional shareholders reporting positions in this security for the Q2 2016 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2016 vs Q1 2016 Across Filers

Q1 2016 holders

487

Q2 2016 holders

473

Holder diff

-14

Investor	Q1 2016 Shares	Q2 2016 Shares	Share Diff	Share Chg %	Q1 2016 Value $	Q2 2016 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.